ANI Pharma (ANIP) Misses Q4 EPS by 8c, Offers FY Guidance

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.52, $0.08 worse than the analyst estimate of $0.60. Revenue for the quarter came in at $18.04 million versus the consensus estimate of $18.13 million.

GUIDANCE:

ANI Pharma sees FY2016 revenue of $105-120 million, versus the consensus of $91.8 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chroni
• Sanuwave Q2 2026 revenue tops revised guidance range
• DHT Holdings Q2 TCE earnings estimated at $126,700 per day